MEDICAL MARIJUANA

InMed Pharmaceuticals disrupting cannabinoid space with biosynthesis technology



InMed Pharmaceuticals Inc (TSX:IN; OTCQX:IMLFF) Chief Business Officer Josh Blacher speaks with Proactive Investor’s Christine Corrado about how the biopharma company is changing the game in the cannabinoid space.

Blacher says the Vancouver based company, which specializes in developing therapeutics to treat a variety of diseases, is disrupting the space with its cannabinoid biosynthesis technology, which aims to manufacture any of the more than 90 variations of cannabinoids, resulting in products that are bio-identical to the naturally occurring cannabinoids in the cannabis plant.

source

Leave a Reply

Your email address will not be published. Required fields are marked *